{"name":"Voronoi, Inc","slug":"voronoi-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"VRN110755","genericName":"VRN110755","slug":"vrn110755","indication":"Other","status":"phase_1"},{"name":"VRN101099","genericName":"VRN101099","slug":"vrn101099","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"VRN110755","genericName":"VRN110755","slug":"vrn110755","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VRN101099","genericName":"VRN101099","slug":"vrn101099","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQU2kzeGtqMVd0ckxBRHBiNjlteS0ybnJMZm9zNkJvbFNLcHVZWUpEV1lpbEVDNHhYeDA5Z0pCV2VUNWQ0MUNDRWZqRzZkbWZKOERHU1FhaWo1WFhBS0FJeTZFaDdmUzRjZXlLQ3NtV0h0QmNSeXdhR1Nfc3p4UGFTSjllNnc2VlZWbVFCWjgtSGIzNWUxQ2c?oc=5","date":"2026-01-06","type":"earnings","source":"Voronoi by Visual Capitalist","summary":"Soros vs. Druckenmiller — Q3 2025 Portfolio Contrast - Voronoi by Visual Capitalist","headline":"Soros vs. Druckenmiller — Q3 2025 Portfolio Contrast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPLXVtOUlTeUJ5YlVSanlndEhxdnFGd3VnZWM4V2Q1cFgtUnlaQkFZM254WGxaUXc4eEFIa3FZQ2o5dnVVMG1pdTdOLXBPbnJKa3FFYzJGYi1oWkFBeFVfNndVbGZDZ3VadHVlTkk0TGlFN2tGSnFtbWVVZDFkNkdManlmX3BxTTZHMmxXWEFKYnFpVEZsNjBudG40bks?oc=5","date":"2026-01-02","type":"pipeline","source":"Voronoi by Visual Capitalist","summary":"Stan Druckenmiller’s Portfolio — 10-Year Strategic Shift - Voronoi by Visual Capitalist","headline":"Stan Druckenmiller’s Portfolio — 10-Year Strategic Shift","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE05MVlJZVVsRUdiZENoRjBPN2dNVlZ0R0x2VzlXVU9oYnNtc01rMk1KVXpZZGNHbDFTNnlXTXBKR0NGTHZnNFEyTWNjQzVNVERLMGo1X05jQktnSHFPUEFmS3J0OWVxcTJpazFfVWdn0gFyQVVfeXFMTklaUkVkQkt0UEJMVmw0MkJIeGxuSjBvbWtGVndCdnRjNXQ3Mm1KYmdaN1I3dWdlN0lWN0NCd0lTQ0dmRHZrTDBaZTVpcEszYjdxdF9TUm1oNGM1aUdpdHdoZnpKTFVmc2t4WHMwVHdPOWF3?oc=5","date":"2025-12-24","type":"pipeline","source":"koreabiomed.com","summary":"Voronoi’s 4th-gen EGFR candidate VRN11 shows distinct signal beyond Tagrisso - koreabiomed.com","headline":"Voronoi’s 4th-gen EGFR candidate VRN11 shows distinct signal beyond Tagrisso","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQRFJHM0JPd2NWRWkxLWJKR3hYckVFRThqS1VBeDNHdUlrY296aHYtWFFyQUQwZjF1bDFwVkh2NU5SUU9WcnJxOTRSTzdhU053N2RwS2RxUERoS2c5WXJHcnFITFN3dzlwSlJoMW9CODZLQmRBTDk4bWNSVmVnV2pyNVNrYm5oYm5CWmc5bDFWekttVzdKR01BZ1lDQkpUUm1hZUVzLUo0UVN1R1BQ?oc=5","date":"2025-12-01","type":"earnings","source":"Voronoi by Visual Capitalist","summary":"Andreas Halvorsen’s Q3 2025 Portfolio — Viking’s Strategic Allocation - Voronoi by Visual Capitalist","headline":"Andreas Halvorsen’s Q3 2025 Portfolio — Viking’s Strategic Allocation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQWHRzSS1xM3pzcFhhaE5XSDlsRnNMUk55YXlvM2twSGk2U1lsUnRFSklZSzdhRGNGMUk0WjhrSWNhb2dtN0tXdlo4bmVwZVl0elBmUngzbjdHcUxESXRveWdHUVNmcHFXczNPNmdPd1dKMUpMTmZPeFRZcXU5Q08zY3o3WHN0RUtudkdVWXV1TURYTWlDOHpaYnoyTWxTLUhXdk1rS0RjckYxVTZoaUtycG5GOUtwa3V2cUQtRnZ2cHlTUQ?oc=5","date":"2025-11-24","type":"earnings","source":"Voronoi by Visual Capitalist","summary":"Stanley Druckenmiller’s Q3 2025 Portfolio: Healthcare Conviction Meets Macro Hedging - Voronoi by Visual Capitalist","headline":"Stanley Druckenmiller’s Q3 2025 Portfolio: Healthcare Conviction Meets Macro Hedging","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNbmZRcTlhYVczbFM2RF9FTno1M0VtNXhDeHFCQzAzMEd6R2VlT0tZZDQtREZPYXotVm45ZUdGekdQU3Zxb0E3eV85VW45ci1raUtUQnNjUl9MWXEyaWlsQTBDSmdOTHJKVnhQUExwSm11azdKTEtQU2trejI0WjNjejV5V1dvUjdzRlZETnRqZXJ3cDdESXZUYlJ1MlFkZkQ5Mmx2UFBaa1pvMnVYNjN2ejBKanpNVWJNaGhDOHR5eEtDRDhsbTl1eFJIYWdsQXJVREc4aw?oc=5","date":"2025-11-18","type":"pipeline","source":"Forbes","summary":"New AI-Powered Cancer Drugs Fuel Share Rally Of Korea’s Voronoi, Minting A New Billionaire - Forbes","headline":"New AI-Powered Cancer Drugs Fuel Share Rally Of Korea’s Voronoi, Minting A New Billionaire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiQkFVX3lxTE9WeWJNQjd6MFVubGFHWnpqVldsTGktNnB3V3JlWWNSMlJ0YW1EVjJ4YU9iX1VFMHZnUGxiXzJtQWZLUQ?oc=5","date":"2024-08-27","type":"deal","source":"코메디닷컴","summary":"Voronoi's Global Licensing Deal Sparks Optimism for \"Continued Success\" - 코메디닷컴","headline":"Voronoi's Global Licensing Deal Sparks Optimism for \"Continued Success\" - 코메디닷컴","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1lU1c4Z0J6MHdyeDJfMThlYmNoNTVHeTRjYXR1OTVTM1c5R1hWRFk3SDhTX1Y5ay01enhsYVNUbGZ0UTdlVkcwNWVIa0JtREp1NGdza1JDOTZwWl9qb2ZDOVh1UmVlaU9nbV9LdjV30gFyQVVfeXFMUGJxdUZ3WXB6VjdOb3JlSzVKelkxOU5yNEo3bjE5TE9sODRkYWYxZS16UGVVVHBocEozV19tQ21uczB2OVV0Y1FBaDdsbzRlMkV1RFpDMC12cXRkeHBoUF94aTNBTUF5R2dxRl9OVC1uSjNR?oc=5","date":"2024-07-16","type":"trial","source":"koreabiomed.com","summary":"Voronoi withdraws from US phase 1 trial for NSCLC drug - koreabiomed.com","headline":"Voronoi withdraws from US phase 1 trial for NSCLC drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9hLVZzM2ZwaVdnSHQ1REg4VF9PUUg4QWoyelBILUlabHU3RWJGaGlsUVpkSXltWUhCTFdYLXM4Nk5sUGpKQjZhdFZHekpYSW5LQUVPYVpsaTd1a29raGM2WEotWmtfUWlWR3AzRkp3?oc=5","date":"2023-08-28","type":"pipeline","source":"KED Global","summary":"Voronoi to strengthen AI-driven open innovation - KED Global","headline":"Voronoi to strengthen AI-driven open innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPOEhDUG1hRWF5MGUwTGRvb0NsSm1KV2ZvcXVoQTJSb1JTN28tUDh1WWkzd3pZRHc1a1FfRmFBZkpsWTNabHNRT2tVNlFmMDdYVHRKT2Z1eTAzdG5VbjdpelE0aGs1TGk3YmNOaWhmWDg4WG5sWVJiZ053SUlZT0RRel9ETko3ZDQwTGllOXNWMG5ZMElhNVNzdHV3YzFlV0NmeWxwTDFUOWdBR3ZjOUJzeXYxN1FnWjQxZ054VEJn?oc=5","date":"2022-09-13","type":"deal","source":"Business Wire","summary":"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi - Business Wire","headline":"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1MLVFBOUJ3aGE0eUc2cXg2YlN0NkpUQ0ROTlB2cFBUX0VFcDVRQ092MTZ2anRFNzZzTFFOQlYyMnVYdDlraFA4d2xXUlhTd09LUjdTdkoweXRfNS1sV2t2U2hkYUZEYzJsV0dScW5fd0Vidw?oc=5","date":"2022-03-04","type":"pipeline","source":"KED Global","summary":"Korea’s Voronoi in talks with global firms on drug designs - KED Global","headline":"Korea’s Voronoi in talks with global firms on drug designs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9YMGdqYnBGdVlsSVZrLVNOUTZ0bTFvenRQR2dNRWVTM3lpSUY1U2YzUTJLMmFwZC01VmtXeFRIM0FmdUR4dWU0dTZMeE9uaDVDZmpudGhyM1NvajhCSFVyTjg0R28tbUNROHc?oc=5","date":"2021-09-02","type":"deal","source":"KED Global","summary":"Korea’s bio startup Voronoi inks $324 million deal with Brickell Biotech - KED Global","headline":"Korea’s bio startup Voronoi inks $324 million deal with Brickell Biotech","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":8,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}